$OCGN read this as I told you for a long time there will be no approval. Investors are essentially betting on the notional value of the agreement between Bharat Biotech and Ocugen. Things don't look well. The anticipated release date of Covaxin coincides with the near completion of vaccination programs in the country. Hence, many believe that it would not be able to land any orders for Covaxin.